Introduction {#s1}
============

Cell lineage specification is typically accompanied by changes in DNA cytosine methylation, most of which occur at CpG dinucleotides in somatic cells ([@bib37]; [@bib60]). This prototypical epigenetic modification, once regarded as static, is now known to be remarkably dynamic ([@bib61]; [@bib78]). DNA methyltransferases (DNMTs) convert cytosine to 5-methylcytosine (5mC)([@bib82]); subsequently, proteins of the TET dioxygenase family oxidise 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)([@bib26]; [@bib35]; [@bib61]; [@bib72]). These modified bases, together termed oxidized methylcytosines (oxi-mC), facilitate DNA demethylation and are also epigenetic marks in their own right ([@bib57]; [@bib71]).

Much of the interest in TET proteins has centered around the possibility that oxidised methylcytosines are intermediates in one or more pathways of DNA demethylation ([@bib61]; [@bib78]). In one well-documented mechanism, the maintenance DNA methyltransferase complex DNMT1/UHRF1 complex restores symmetrical methylation to the hemi-methylated CpGs that are formed upon DNA replication ([@bib60]). However, 5hmC, 5fC and 5caC all inhibit this process, thus causing \'passive\' (replication-dependent) DNA demethylation. In a second mechanism, 5fC and 5caC are substrates for excision by TDG and subsequent \'active\' demethylation through base excision repair ([@bib26]; [@bib66]; [@bib68]). Thus TET-mediated oxidation of 5mC to 5hmC, 5fC or 5caC facilitates replication-dependent DNA demethylation on the one hand, and replication-independent excision of 5fC and 5caC followed by their replacement with unmodified C on the other hand.

B cells are an essential component of the adaptive immune system, which are selected to expand and subsequently undergo somatic hypermutation and immunoglobulin (Ig) class switching on the basis of their ability to produce high affinity antibodies that provide immunity against pathogens ([@bib1]; [@bib8]; [@bib75]). B cell development in the bone marrow involves step-wise rearrangement of the genes encoding Ig heavy and light chains, which combine to form the B cell antigen receptor (BCR). The Ig heavy chain locus, Igμ, is rearranged first at the pro-B cell stage. Subsequently, the pre-BCR (formed by pairing the rearranged heavy chain with a surrogate light chain) reactivates Rag expression and stimulates rearrangement of an Ig light chain locus (Igκ or Igλ) at the pre-B cell stage; the Igκ locus predominates, accounting for over 95% of all productively rearranged light chains expressed on B cells in mice. Prior to rearrangement, there are two non-coding germline transcripts from the κ locus, C**κ** and Ig**κ**, which are closely correlated with the rearrangement potential of the locus.

As in many other cell types, extensive changes in DNA cytosine modification are observed at a genome-wide level during B cell development ([@bib45]). Specifically, Ig locus rearrangement requires activation of tissue-specific enhancers, a process typically accompanied by changes in DNA and histone modification. In mature B cells, only the rearranged allele of Igκ is demethylated, whereas the unrearranged allele remains methylated. It was thus postulated that methylation suppresses Ig**κ** locus accessibility and that differential methylation may contribute to allelic exclusion; however, subsequent studies found that both κ alleles can be expressed in mature B cells, even though one allele is methylated ([@bib47]). Conversely, analysis of Dnmt1-deficient pre-B cells (which lose DNA methylation at both alleles of the Ig**κ** locus) indicated that demethylation of the Ig**κ** locus was not sufficient to induce locus rearrangement and expression ([@bib12]). Therefore, the relation between DNA methylation and Ig locus rearrangement remains to be fully elucidated at a molecular level.

Here we have examined the role of TET proteins in B cell development. Three TET enzymes, TET1, TET2 and TET3, are expressed in mammalian cells. In mice, Tet1 is highly expressed in the embryo and in embryonic stem cells ([@bib36]; [@bib43]), whereas Tet2 and Tet3 are abundantly expressed in somatic cells including hematopoietic cells. Using mice doubly deficient for Tet2 and Tet3 in early B cells, we show that TET function is required for developing B cells to transit from the pro-B to the pre-B stage. Tet2 and Tet3 regulate germline transcription and rearrangement of the Ig**κ** light chain, and synergize with B lineage-specific transcription factors such as E2A and PU.1 to promote DNA demethylation and chromatin accessibility at B cell enhancers. TET catalytic activity is required for IRF4 expression, but IRF4 cannot restore Ig**κ** germline transcription or the demethylation status of the Ig**κ** enhancers in the absence of Tet2 and Tet3. Our results suggest that TET enzymes regulate multiple aspects of B cell development at the pro-B to pre-B cell transition, and demonstrate a causal relationship between DNA modification and chromatin accessibility.

Results {#s2}
=======

Loss of TET function in B cells impairs B cell development at the pro-B to pre-B transition {#s2-1}
-------------------------------------------------------------------------------------------

*Tet2* and *Tet3* mRNAs are abundantly expressed at all stages of B cell development, whereas *Tet1* mRNA is expressed at much lower levels ([@bib42])([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, *left, blue bars*). However neither *Tet2^-/-^* mice (which are fully viable and fertile \[[@bib41]\]) nor *Tet3^fl/fl^ Mb1Cre* mice (which we generated to bypass the perinatal lethality of *Tet3-/-* mice \[[@bib22]\]) displayed any striking B cell phenotypes ([Figure 1---figure supplement 1B, C and D](#fig1s1){ref-type="fig"} and *not shown*). To assess the effect of a profound loss of TET function in B cells, we generated *Tet2^-/-^ Tet3^fl/fl^ Mb1Cre* mice (here termed *Tet2/3* DKO mice), in which a conditional *Tet3* allele ([@bib40]) is deleted in the context of a germline deletion of *Tet2* at the transition from pre-pro B cells to pro-B cells ([@bib28]). As judged by DNA dot blot using an anti-5hmC antibody, 5hmC levels were at least 4-fold lower in vitro-cultured pro-B cells of *Tet2/3* DKO mice compared to wild type (WT) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, right).

*Tet2/3* DKO mice showed a striking reduction in the percentages and numbers of B cells in the bone marrow compared to WT mice, with a partial block at the pro-B to pre-B transition ([Figure 1](#fig1){ref-type="fig"}). The percentage of B220^+^CD19^+^ cells in the *Tet2/3* DKO bone marrow was substantially reduced (\<50% of that in WT bone marrow) at 7--8 weeks and even more pronounced (\<10%) at 11--12 weeks of age ([Figure 1A](#fig1){ref-type="fig"}). The percentages and numbers of pre-B cells (CD43^low^B220^+^IgM^-^) and immature B cells (CD43^low^B220^+^IgM^+^) in the *Tet2/3* DKO bone marrow at 11--12 weeks were 7--20% of those in the WT bone marrow ([Figure 1B--D](#fig1){ref-type="fig"}); concomitantly, the percentages and numbers of re-circulating (mature) IgM^+^IgD^+^CD19^+^ B cells in the bone marrow were also greatly diminished in *Tet2/3* DKO mice ([Figure 1C,D](#fig1){ref-type="fig"}). Because B220 and CD43 are co-expressed not only on B cells but also on plasmacytoid dendritic cells, we reanalyzed CD19^+^B220^+^ bone marrow cells based on c-kit and CD25 expression; this analysis confirmed that percentages and numbers of pre-B cell (IgM^-^CD19^+^B220^+^ckit^--^CD25^+^) were substantially reduced in *Tet2/3* DKO mice ([Figure 1E](#fig1){ref-type="fig"}). In parallel, *Tet2/3* DKO mice showed an increased percentage of pro-B cells (IgM^-^CD19^+^B220^+^ckit^+^CD25^--^) in the bone marrow ([Figure 1E](#fig1){ref-type="fig"}, left), but total pro-B cell numbers were unaltered because of the overall decrease in total B-lineage cells ([Figure 1E](#fig1){ref-type="fig"}, right). Consistent with these findings, there was a reduction in the percentage and number of mature B cells in the spleen ([Figure 1F](#fig1){ref-type="fig"}).10.7554/eLife.18290.002Figure 1.Loss of Tet2 and Tet3 in the B cell lineage results in B cell developmental blockade in vivo.(**A**) Reduced bone marrow B cells (B220^+^ CD19^+^) in *Tet2^-/-^Tet3^fl/fl^ Mb1Cre* (*Tet2/3* DKO) mice. Total bone marrow cells from wild type (WT) or *Tet2/3* DKO mice at eight weeks (upper) and 11 weeks (lower) were analyzed for the percentage of total B cells (CD19^+^B220^+^) by flow cytometry and the representative plots are shown. Note that the loss of B cells is apparent at 8 weeks and more pronounced at 11 weeks. (**B**) *Tet2/3* DKO mice display a striking reduction in pre-B cells. Bone marrow pre-B cells (IgM^-^CD43^-^B220^+^) were analyzed by flow cytometry and representative plots are shown. The absolute numbers of pre-B cells in 8--12 week-old mice are shown in [Figure 1D](#fig1){ref-type="fig"}. (**C**) Reduced frequency of immature (IgM^+^IgD^-^) and mature recirculating (IgM^+^IgD^+^) B cells in DKO bone marrow. CD19^+^B220^+^ bone marrow cells from 10 week-old *Tet2/3* DKO and WT mice were analyzed for cell surface IgM and IgD expression. Data shown are representative and numbers of immature and mature B cells from four mice are shown in **[Figure 1D](#fig1){ref-type="fig"}.** (**D**) Quantification of cell numbers in multiple experiments similar to those shown in [Figure 1B and C](#fig1){ref-type="fig"}. (**E**) B cell development in *Tet2/3* DKO mice is blocked at the transition from the pro-B cell to the pre-B cell stage. Bone marrow B cells (CD19^+^B220^+^) of *Tet2/3* DKO or WT mice (eight weeks) were analyzed by flow cytometry for c-kit and CD25 expression. *Left panel*, Representative flow cytometry plots; *right panel*, numbers of bone marrow B cells at pro-B and pre-B cell stages were compared between WT and *Tet2/3* DKO mice (n = 4). Pro-B cells, CD19^+^B220^+^IgM^-^CD25^-^c-kit^+^; pre-B cells, CD19^+^B220^+^IgM^-^CD25^+^ c-kit^-^. (**F**) *Tet2/3* DKO mice have reduced splenic B cells. Total splenocytes from WT or *Tet2/3 DKO* mice were analyzed for B220 and CD19 expression by flow cytometry. *Left panel*, representative flow cytometry plots. *Right panel*, numbers of splenic B cells in WT and *Tet2/3* DKO mice (n = 3 for each age group). (**G**) Accumulation of B cells lacking surface IgM or IgD expression in the periphery of *Tet2/3* DKO mice. B cells (CD19^+^B220^+^) were analyzed for IgM and IgD expression. *Left panel*, representative flow cytometry plots. *Right panel*, compiled data of IgM^-^IgD^-^ % from multiple experiments. *Tet2/3* DKO mice show a considerable age-dependent increase in the proportion of IgM^-^IgD^-^ B cells lacking surface B cell receptor. (**H**) IgM^-^IgD^-^ B cells in the Tet2/3 DKO mice expressed high level of TdT (upper panel) and preBCR (CD179a, lower panel). Ages of mice are shown on the right for (**A**), (**B**), (**F**), and (**G**). Error bars indicate standard deviations. \*, p\<0.05, \*\*, p\<0.01 by Student's *t* test. ns, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.002](10.7554/eLife.18290.002)10.7554/eLife.18290.003Figure 1---figure supplement 1.Tet2 and Tet3 are redundantly required for B cell development and BCR expression.(**A**) *Right*, floxed *Tet3* alleles are efficiently deleted in *Tet2^-/-^Tet3^fl/fl^* pro-B cells transduced with Cre-IRES-GFP retrovirus. Expression of *Tet1*, *Tet2* and *Tet3* mRNA in Cre^+^ (GFP^+^) WT and *Tet2^-/-^Tet3^fl/fl^* pro-B cells was measured by real time qRT-PCR. *Left*, genomic DNA was isolated from WT and *Tet2/3* DKO pro-B cells and the overall level of 5hmC was detected by anti-hmC dot plot. (**B**) B cell development in the bone marrow is normal in the absence of *Tet3. Tet3^fl/fl^ Mb1-Cre* mice (12 week-old) were analyzed. Shown are representative FACS plots for B220 and CD43 expression in the bone marrow (*top panel*) and c-kit and CD25 expression in the CD19^+^B220^+^IgM^-^ bone marrow cells (*lower panel*). (**C**) Normal B cell compartment in the periphery of *Tet3^fl/fl^ Mb1-Cre* mice. As in (**B**) splenocytes were analyzed for expression of CD19 and B220 (*upper panel*); IgM and IgD expression of CD19^+^B220^+^ B cells (*lower panel*). (**D**) Normal expression of cell surface Igκ in splenic B cells from Tet2-KO or Tet3-KO. Cell surface Igk was analyzed by flow cytometry as in [Figure 2A](#fig2){ref-type="fig"}. (**E**) Ig^+^ cells from *Tet2/3* DKO mice have variable levels of residual *Tet3* mRNA expression. Ig^+^ (IgM^+^IgD^+^) or Ig^-^ (IgM^-^IgD^-^) splenic B cells (CD19^+^B220^+^) were sorted and Tet3 expression was determined by real-time qRT-PCR. (**F**) Compared to WT mice, *Tet2/3* DKO mice have higher frequencies of myeloid cells in the spleen and bone marrow. Shown are representative flow cytometry plots of CD19 and CD11b staining. Frequencies of B cells (CD19^+^CD11b^-^) and myeloid cells (CD19^-^CD11b^+^) are indicated. (**G**) Formation of splenomegaly and lymphadenopathy in *Tet2/3* DKO mice. Lymph nodes and spleen from a representative *Tet2/3* DKO mouse and littermate control (*Tet2^+/-^ Tet3^fl/+^)* at 20-week of age are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.003](10.7554/eLife.18290.003)

A large fraction of CD19^+^B220^+^ B cells in the spleen of *Tet2/3* DKO mice lacked cell-surface IgM and/or IgD expression (\~25% and\~45% IgM^--^IgD^--^ cells in eight week-old and 11 week-old *Tet2/3* DKO mice respectively; [Figure 1G](#fig1){ref-type="fig"}) These peripheral Ig-negative B cells expressed a significantly higher level of Terminal deoxynucleotidyl transferase (TdT) and pre-BCR (VpreB, also known as CD179α), thus displaying the expression profile of developing pro-B cells ([Figure 1H](#fig1){ref-type="fig"}); they also uniformly lacked expression of *Tet3* mRNA, indicating complete deletion of the *Tet3* allele ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). In contrast, two out of 3 surface Ig-positive cell samples analyzed showed residual expression of *Tet3* mRNA ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). Together, these data suggest that the surface Ig-positive cells in *Tet2/3* DKO mice were 'escapees' that had not completely deleted the *Tet3* allele, and hence had expanded due to the proliferative advantage of B cells expressing a cell-surface B cell receptor (BCR) ([@bib44]).

Notably, there was a detectable expansion of CD11b^+^ myeloid-lineage cells in the bone marrow and spleen of *Tet2/3* DKO mice ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}), resembling the myeloid skewing observed in mice deficient in Tet2 or Tet3 alone in the hematopoietic compartment ([@bib41], [@bib40]). Moreover, all older *Tet2/3* DKO mice developed B cell lymphomas with splenomegaly and lymphadenopathy by the time they were five months old ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}). These findings are reported here for completeness, but will be pursued in a separate study. The data recall the late B cell malignancies observed in germline Tet1-deficient mice ([@bib13]), and reinforce the notion that TET loss-of-function is associated with hematopoietic malignancies ([@bib33]; [@bib40]).

Tet2 and Tet3 regulate κ chain expression and the DNA modification status of Igκ locus enhancers in vivo {#s2-2}
--------------------------------------------------------------------------------------------------------

The splenic *Tet2/3* DKO B cells that lacked cell-surface IgM and/or IgD expression ([Figure 1G](#fig1){ref-type="fig"}) also showed greatly reduced expression of cell-surface and intracellular Ig**κ** light chains ([Figure 2A](#fig2){ref-type="fig"}) and impaired Ig**κ** rearrangement ([Figure 2B](#fig2){ref-type="fig"}). Furthermore, purified pre-B cells from *Tet2/3* DKO mice showed a marked reduction (\>50%) in Vκ-Jκ1 rearrangement compared to their WT counterparts ([Figure 2C](#fig2){ref-type="fig"}), demonstrating that TET function is important for Ig**κ** locus rearrangement and κ chain expression in developing B cells and hence critical for the generation of mature B cells with functional B cell receptors.10.7554/eLife.18290.004Figure 2.Tet2 and Tet3 promote immunoglobulin chain expression and rearrangement in vivo.(**A**) IgM^-^IgD^-^ B cells in the *Tet2/3* DKO mice have diminished immunoglobulin light chain expression. IgM^-^IgD^-^ and IgM^+^IgD^+^ splenic B cells (CD19^+^B220^+^) were analyzed for intracellular (*left panel*) and cell surface (*right panel*) Ig**κ** expression by flow cytometry. Data are representative of three independent experiments. (**B**) *Tet2/3* DKO pre-B cells have reduced Ig**κ** rearrangement. WT and *Tet2/3* DKO pre-B cells (CD19^+^ckit^-^CD25^+^) were isolated from bone marrow by cell sorting and the Ig**κ** rearrangement was determined by PCR amplification with Ig**κ** intron as loading control. Representative experiment of three is shown. (**C**) Vκ-Jκ1 rearrangement is impaired in the *Tet2/3 DKO* pre-B cells. Rearrangement of Vκ-Jκ1 was quantified by real-time PCR. Data are summary of four pairs of mice and were normalized to the signal from WT. \*\*, p\<0.01 by Student's *t* test.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.004](10.7554/eLife.18290.004)

TET proteins are known to facilitate both active and passive DNA demethylation at gene bodies, promoter-TSS regions and enhancers (\[[@bib30]; [@bib63]; [@bib61]; [@bib74]\] and *below*). To ask whether loss of TET function in *Tet2/3* DKO B cells affected Ig**κ** expression through changes in DNA modification, we analyzed the DNA modification status of known *cis*-regulatory elements in the Ig**κ** locus ([@bib34]; [@bib81]) ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The 3' enhancer (3'Eκ) and a more distal 3' enhancer (dEκ) contain 2 and 3 CpG dinucleotides respectively; the intronic Eκ enhancer (iEκ) contains no CpGs and was not considered further ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Using bisulfite sequencing (which does not distinguish 5hmC from 5mC, or 5fC and 5caC from unmodified C \[[@bib31]; [@bib61]\]), we found that all 5 CpG sites in the 3' and distal Eκ enhancers were fully \'methylated\' (5mC + 5 hmC) in LSK (Lin*^-^*, Sca1^+^ c-kit^+^) cells, a population enriched in hematopoietic stem/precursor (HSPC) cells ([@bib29]); began to lose this modification at the pre-pro-B cell stage; were partially methylated in pro-B cells; and almost completely \'unmethylated\' (C/5fC/5caC) in WT splenic CD19^+^ B cells ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Examination of publicly available data for human HSC, neutrophils and B cells showed that the corresponding human enhancers also undergo B cell-specific \'demethylation\' (loss of 5mC/5hmC; [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}).10.7554/eLife.18290.005Figure 3.Tet2 and Tet3 promote germline transcription of the Igκ locus and demethylation of the 3' and distal Eκ enhancers.(**A**) The Igκ locus. Diagram depicts gene segments and regulatory elements of the Ig**κ** locus. For sequences of the 3' and distal Eκ enhancers, see **[Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}.** (**B**) Flow-chart depicting generation of *Tet2/3* DKO pro-B cells in vitro. Bone marrow (BM) cells from wild type (WT) or *Tet2^-/-^Tet3^fl/fl^* mice were cultured on OP9 stromal cells with IL-7 (10 ng/ml) for one week, then transduced with Cre-IRES-GFP retrovirus. GFP^+^ cells were isolated by cell sorting five days later, and cultured on OP9 cells with IL-7 for an additional week. At the end of this period, all cells expressed similar surface markers (B220^+^CD43^+^IgM^-^), consistent with the phenotypes of pro-B cells ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). *Tet3* deletion efficiency was \>90% (not shown). (**C**) Acute loss of TET function results in increased DNA 'methylation' (5mC + 5 hmC) at the 3' and distal Eκ enhancers. In vitro-derived pro-B cells from WT, *Tet2* KO and *Tet2/3* DKO mice were analyzed for the DNA modification status of 3' and distal Eκ enhancers by bisulfite treatment of genomic DNA followed by PCR amplification and sequencing on an Illumina MiSeq platform. Error bars show the standard deviation of three independent experiments. (**D**) Tet2 and Tet3 are required for germline transcription of the Ig**κ** locus and *Irf4/8* in pro-B cells. *Top*, Diagram of the Igκ locus and the primers used to detect germline and Cκ transcription. *Bottom*, WT, *Tet2* KO and *Tet2/3* DKO pro-B cells were analyzed by real time PCR for expression of indicated genes. mRNA expression was normalized to that of *Actb*, and mRNA levels in WT cells were set to 1. Note the almost complete absence of germline and Cκ transcription in *Tet2/3* DKO pro-B cells. Error bars represent the standard deviation of three independent experiments. \*\*, p\<0.01 in Student's *t* test. (**E**) Loss of TET function in vivo is accompanied by increased DNA 'methylation' (5mC + 5 hmC) at the 3' and distal Eκ enhancers. CD19^+^ cells were isolated from spleens of WT, Tet2KO (*Tet2^-/-^Tet3^fl/fl^*) and *Tet2/3* DKO (*Tet2^-/-^Tet3 ^fl/fl^ Mb1Cre*) mice, and the DNA modification status of the 3' and distal Eκ enhancers was determined as in (**C**). Error bars indicate the range of values obtained in two independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.005](10.7554/eLife.18290.005)10.7554/eLife.18290.006Figure 3---figure supplement 1.The 3'Eκ and distal Eκ enhancers undergo B cell specific-loss of cytosine modification.(**A**) DNA sequences of the 3'Eκ and distal E**κ** enhancers. CpG dinucleotides, consensus E-box, IRF, PU.1, and FKH motifs are indicated. (**B**) The 3'E**κ** and distal E**κ** enhancers undergo B cell-specific DNA 'demethylation'. Control cell types and B cells at various developmental stages indicated were sorted and the DNA modification status (5mC + 5 hmC) of the 3'Eκ and distal E**κ** enhancers were analyzed by bisulfite sequencing as in **[Figure 3C](#fig3){ref-type="fig"}.** (**C**) The 3'E**κ** and distal E**κ** enhancers undergo B cell-specific 'demethylation' (loss of 5mC + 5 hmC) in human B cells. Shown is the DNA modification status of human hematopoietic stem/ precursor cells (HSPC), neutrophils and B cells based on published whole-genome bisulfite sequencing data (GSE31971)([@bib29]). Bars indicate the average fractional modification of each CpG. The regions corresponding to the 3'E**κ** and distal E**κ** enhancers are indicated with rectangles. Note CpG sites outside of the enhancers remain fully methylated in B cells.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.006](10.7554/eLife.18290.006)10.7554/eLife.18290.007Figure 3---figure supplement 2.Tet2/3 regulate Igκ expression and rearrangement in BCR-Abl transformed pre-B cells.(**A**) In vitro-derived WT and *Tet2/3* DKO pro-B cells express similar level of pro-B surface markers. Cell-surface expression of B220, CD43, IgM, and CD127 on WT, control (*Tet2^-/-^ Tet3^f/f^*) and DKO (*Tet2^-/-^ Tet3^f/f^ Cre-GFP*) was analyzed by FACS. (**B**) *Right*, genome-wide 5hmC distribution in WT and *Tet2/3 DKO* pro-B cells was mapped as described in Material and Methods. Axes represent the normalized number of reads (reads per 10^7^) in mapped 5hmC-enriched regions combined from WT and *Tet2/3* DKO. A PCR-amplified, 5hmC-containing spike-in control was used for normalization between WT and DKO (spike-in). Note that the overall 5hmC level decreased dramatically in the *Tet2/3* DKO cells. Level of 5hmC in *Tet2/3* DKO pro-B cells across different type of regions was plotted as in [Figure 4B](#fig4){ref-type="fig"}. (**C**) Decreased IRF4 protein in *Tet2/3* DKO pro-B cells. The protein level of E2A and IRF4 was determined by immunoblotting with GAPDH as loading control. (**D**) Decreased Ig**κ** germline transcription in DKO Abl-transformed pre-B cells. BCR-Abl transformed WT and *Tet2/3* DKO pre-B cells were treated with Gleevec for 3 or 7 hr and the Ig**κ** germline transcript expression were quantified by qRT-PCR. (**E**) Recombination of the Ig**κ** locus is greatly diminished in *Tet2/3* DKO pre-B cells. Ig light chain rearrangement was induced by Gleevec treatment as in (**D**) and the induction of DNA double-strand (ds) breaks in the Jκ1 RSS (Recombination Signal Sequence) region was determined by qRT-PCR. The results were normalized to those observed in vehicle (DMSO)-treated cells. The data summarize two independent experiments. \*\*, p\<0.01 in student's *t* test.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.007](10.7554/eLife.18290.007)

Tet2 and Tet3 regulate demethylation of Igκ locus enhancers and Igκ germline transcription *in vitro* {#s2-3}
-----------------------------------------------------------------------------------------------------

To analyze the defects in *Tet2/3* DKO B cells at a molecular level, we used a well-characterized cell culture system ([@bib76]) in which TET loss-of-function could be acutely induced. *Tet2^-/-^Tet3^fl/fl^* bone marrow cells were cultured for one week with IL-7 and OP-9 feeder cells to generate pro-B cells (also known as large pre-B or pre-B II cells), then retrovirally transduced with Cre-IRES-GFP or control empty IRES-GFP retrovirus to delete the floxed *Tet3* allele ([Figure 3B](#fig3){ref-type="fig"}). The efficiency of *Tet3* deletion was \>90%, and there was only a slight compensatory upregulation of *Tet1* mRNA ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, *left*, *red and green bars*). Under these conditions, expression of surface markers in Cre-transduced *Tet2^-/-^Tet3^fl/fl^* pro-B cells (termed *Tet2/3* DKO pro-B cells) was indistinguishable from those in control cells (WT cells transduced with Cre or *Tet2^-/-^Tet3^fl/fl^* cells transduced with empty vector), with all genotypes exhibiting the typical surface phenotype of pro-B cells (B220^+^, CD19^+^, CD43^high^, IgM^--^, CD127^+^; [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"} and *not shown*).

Bisulfite sequencing showed that in vitro-generated *Tet2/3* DKO pro-B cells displayed a striking increase in DNA modification (5mC + 5 hmC) at the 3' and distal Ig**κ** enhancers and a parallel decrease (\>90%) in C**κ** transcripts and Ig**κ** germline (GL) transcripts compared to control pro-B cells ([Figure 3C and D](#fig3){ref-type="fig"}, *compare blue and green bars*), consistent with the corresponding decreased Ig**κ** expression and increased DNA modification (5mC + 5 hmC) observed in *Tet2/3* DKO B cells compared to WT B cells analyzed ex vivo ([Figures 2A](#fig2){ref-type="fig"} and [3E](#fig3){ref-type="fig"}). The increased modification indeed reflected increased DNA methylation (5mC, not 5hmC), since genome-wide 5hmC mapping by CMS-IP showed almost no remaining 5hmC in *Tet2/3* DKO pro-B cells compared to WT pro-B cells ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}); this is a more reliable technique in terms of signal-to-noise ratio than DNA dot blot analysis with anti-5hmC ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, *right*). In vitro-generated pro-B cells deficient in Tet2 alone (*Tet2^-/-^Tet3^fl/fl^* cells transduced with empty retrovirus, [Figure 3C-3E](#fig3){ref-type="fig"}, *red bars*) showed a partial increase in methylation ([Figure 3C](#fig3){ref-type="fig"}) and a partial reduction in C**κ** and Ig**κ** germline transcripts ([Figure 3D](#fig3){ref-type="fig"}) whereas loss of Tet2 in vivo had no apparent effect ([Figure 3E](#fig3){ref-type="fig"}), suggesting redundant functions of Tet2 and Tet3 in modulating the DNA modification status of these Ig**κ** enhancers and showing that Tet3 can compensate fully for lack of Tet2 in vivo but not in vitro.

Ig**κ** germline transcription and Igκ rearrangement is regulated by the concerted action of multiple transcription factors at the Eκ enhancers, including E2A, EBF1, PAX5, PU.1, IRF4 and IRF8 ([@bib14]; [@bib15]; [@bib25]; [@bib59])([Figure 3A](#fig3){ref-type="fig"}). With the exception of the functionally redundant transcription factors IRF4 and IRF8 which showed decreased expression (*see below*), mRNA and protein levels for most of these known regulators were unchanged in *Tet2/3* DKO pro-B cells compared to WT ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"} and *not shown*). Similarly, *Tet2/3* DKO pre-B cells transformed with BCR-ABL ([@bib11]; [@bib38]) had diminished Ig**κ** germline transcription, both under resting conditions and after treatment with the Abelson kinase inhibitor Gleevec (also known as imatinib or STI-571), which induces Ig**κ** locus activation in BCR-Abl-transformed cells ([@bib58]) ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). Gleevec-treated *Tet2/3* DKO pre-B cells also had significantly reduced formation of Rag-induced DNA double-strand breaks at the Jκ1 segment compared to WT cells ([Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}). These results show that TET proteins demethylate and modulate the activity of Igκ enhancers and thus influence subsequent Igκ rearrangement.

TET proteins promote chromatin accessibility at binding sites for B cell lineage-specific transcription factors {#s2-4}
---------------------------------------------------------------------------------------------------------------

Ig germline transcription requires locus accessibility ([@bib80]). To test whether TET proteins had a role in regulating the accessibility of the Igκ locus, we identified accessible chromatin regions in cultured pro-B cells at a genome-wide level by ATAC-seq (assay for transposase-accessible chromatin using sequencing) ([@bib10]) ([Figure 4](#fig4){ref-type="fig"}). The majority of accessible regions (n = 44668, 79.8%; see [Figure 4](#fig4){ref-type="fig"} legend for details) were 'commonly accessible', i.e. similarly accessible in WT compared to *Tet2/3* DKO pro-B cells ([Figure 4A](#fig4){ref-type="fig"}, *grey dots*). Importantly, 1303 regions (2.2%) were potentially regulated by TET because they were more accessible in WT than in *Tet2/3* DKO pro-B cells ([Figure 4A](#fig4){ref-type="fig"}, WT\>DKO differentially accessible regions (WT\>DKO DARs); *blue dots*). 1192 regions (2.1%) gained accessibility in the *Tet2/3* DKO cells ([Figure 4A](#fig4){ref-type="fig"}, DKO\>WT differentially accessible regions (DKO\>WT DARs); *red dots*), and are likely affected indirectly by TET (*see below*).10.7554/eLife.18290.008Figure 4.Tet2 and Tet3 regulate genome-wide enhancer accessibility in B cells.(**A**) ATAC-seq identifies TET-regulated accessible regions in the genome. WT and *Tet2/3* DKO pro-B cells were generated as described in [Figure 3](#fig3){ref-type="fig"} and used to prepare ATAC-seq libraries with two replicates for each genotype. Accessible regions were identified by MACS2 and reads enrichment at each region was complied by MEDIPS and is shown as mean Reads Per Kilobase per Million mapped reads (RPKM) from two replicates, with each dot represent one accessible region (total region = 55999). Differential accessible regions were identified by MEDIPS with an adjusted *p* value ≤ 0.1. Blue dots indicate regions with higher accessibility in WT, or WT differential accessible regions (WT DAR; n = 1303); red dots indicate regions with higher accessibility in DKO, or DKO DAR (n = 1192); grey dots indicate regions with no statistically significant (p\>0.1) with darker grey indicating regions with less than 4-fold difference (n = 44668) which was used for subsequent analysis as commonly accessible regions. (**B**) 5hmC is highly enriched in WT DARs. Genome-wide distribution of 5hmC in WT pro-B cells was assessed by CMS-IP ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}) and the enrichment of 5hmC across indicated accessible regions (centered and extended ± 1500 bp) was plotted with y-axis showing the mean RPKM. Random genomic regions (n = 44668) were shown as reference for background level of 5hmC. (**C**) TET-regulated WT DARs are primarily distal to transcription start sites (TSS). Distance between regions from (**A**) and closest TSS was plotted on X-axis (log 10) with a number of regions on Y-axis. (**D**) Tet2 and Tet3 regulate the accessibility of enhancers in pro-B cells. The enrichment of H3K4me1 and H3K4me3 ([@bib51]) at regions surrounding ATAC-seq peaks (±250 bp) were analyzed and plotted, with X-axis indicating H3K4me1 and Y-axis indicating H3K4me3. ATAC-seq peaks were classified into promoters (H3K4me1^low^, H3K4me3^high^), enhancers (H3K4me1^high^, H3K4me3^low^), or other regions (H3K4me1^low^, H3K4me3^low^), which may include insulators, silencers and locus control regions. The frequencies of each class of ATAC-seq peaks are indicated. (**E--G**) TET-regulated regions are enriched for E2A and PU.1 binding sites. (**E**) Genome browser view of the 3' end at the Ig**κ** locus. From top to bottom are tracks for ATAC-seq and 5hmC/CMS-IP tracks of WT or *Tet2/3* DKO pro-B cells (combined from two replicates), followed by E2A, PU.1, and H3K4me1 tracks from WT pro-B cells. Rectangles show the locations of the intronic (iEκ), 3' (3'Eκ) and distal Eκ (dEκ) enhancers. (**F**) Left panel shows the ATAC-seq signal from WT (1^st^ column) and DKO (second column) across indicated type of regions, with each horizontal line representing one region/locus. Note that the commonly accessible and randomly sampled regions are compressed compared to WT and DKO DARs in order to accommodate all regions. Right panel shows PU.1 and E2A ChIP-seq signal from published datasets across all regions. Randomly sampled regions are included for comparison. (**G**) Mean RPKM signals of PU.1 (*left*) and E2A (*right*) were shown as a histogram. Note that the WT DARs (blue) have the stronger enrichment of both transcription factors compared to other regions. Analysis of additional transcription factors can be found in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.008](10.7554/eLife.18290.008)10.7554/eLife.18290.009Figure 4---figure supplement 1.Identification of sequence motifs enriched in differential accessible regions.TET-regulated WT \> DKO accessible regions (WT\>DKO DARs; more accessible in WT than in *Tet2/3* DKO pro-B cells) (**A**) and DKO \> WT accessible regions (DKO\>WT DARs) (**B**) were analyzed for enrichment of transcription factor motifs with HOMER with commonly accessible regions (similar accessibility between WT and DKO cells) as background. Top eight motifs from each analysis are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.009](10.7554/eLife.18290.009)10.7554/eLife.18290.010Figure 4---figure supplement 2.Binding pattern of additional B-cell-specific and general transcription factors at accessible regions.ChIP-seq signals ([@bib27]) of CTCF, EBF, Foxo1, and Oct2 (in mature B cells) are plotted for the following regions as in [Figure 4F](#fig4){ref-type="fig"}: TET-regulated WT\>DKO differential accessible regions (DAR; less accessible in *Tet2/3* DKO cells than in WT), DKO\>WT DAR (more accessible in *Tet2/3* DKO than in WT), commonly accessible regions, and randomly sampled regions.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.010](10.7554/eLife.18290.010)10.7554/eLife.18290.011Figure 4---figure supplement 3.Tet2 and Tet3 regulate the accessibility and demethylation of enhancers associated with genes critical for B cell development.Genome browser views of the *Foxo1* (**A**) and *CD79α* (**C**) loci in WT and *Tet2/3* DKO pro-B cells. (**A, C**) From top to bottom are ATAC-seq peaks and 5hmC (CMS) in WT and *Tet2/3* DKO pro-B cell, followed by E2A, PU.1, and H3K4me1 ChIP-seq signal from WT pro-B. (**B, D**) Bisulfite sequencing analysis of the indicated enhancers at the respective locus. Asterisks indicate absence of methylation.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.011](10.7554/eLife.18290.011)

To correlate TET activity and chromatin accessibility, we analyzed genome-wide 5hmC distributed by CMS-IP ([Figure 4B](#fig4){ref-type="fig"}). Compared to randomly sampled regions ([Figure 4B](#fig4){ref-type="fig"}, *dotted line*), all accessible regions displayed higher levels of 5hmC (*solid lines*), suggesting an overall positive correlation between TET activity (5hmC deposition) and chromatin accessibility. DARs that were more accessible in WT than in DKO pro-B cells (TET-regulated DARs, WT\>DKO DARs or simply, WT DARs) exhibited significantly higher levels of 5hmC compared to other accessible regions ([Figure 4B](#fig4){ref-type="fig"}), whereas commonly accessible regions and DARs that were more accessible in DKO than in WT (DKO\>WT DARs or simply, DKO DARs) had lower, comparable levels of 5hmC ([Figure 4B](#fig4){ref-type="fig"}, *compare red and grey lines*), further supporting the notion that TET activity is required to maintain chromatin accessibility. The majority (\>86%) of TET-regulated DARs exhibit the characteristics of enhancers: they are located distal to transcription start sites ([Figure 4C](#fig4){ref-type="fig"}) and are enriched for H3K4me1 over H3K4me3 ([@bib16]; [@bib67]) ([Figure 4D](#fig4){ref-type="fig"}). As expected from this global analysis, TET deficiency greatly decreased the accessibility of the dEκ enhancer ([Figure 4E](#fig4){ref-type="fig"}).

We mined the differentially accessible regions for consensus transcription factor binding motifs, identified by motif enrichment analysis ([@bib27]) and ChIP-seq. Comparing TET-regulated regions (WT\>DKO DARs) to commonly accessible regions, the E-box/ basic region-helix-loop-helix (bHLH) (CANNTG) motif was highly represented, with the second most prominent motif being the composite ETS:IRF (PU.1-IRF) motif ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Consistent with their enrichment for bHLH and ETS binding motifs, WT\>DKO DARs showed strong enrichment for PU.1 and E2A binding sites identified experimentally by ChIP-seq ([@bib27]; [@bib51]), compared to DARs more accessible in DKO than in WT, commonly accessible regions and control random regions ([Figure 4F,G](#fig4){ref-type="fig"}) In contrast, the distribution of binding sites for other relevant transcription factors in pro-B cells ([@bib27]; [@bib51]) either did not show a consistent relation to accessibility (EBF, Oct2) or were similar between WT\>DKO DARs and other accessible regions (Foxo1; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

Other examples of decreased accessibility in *Tet2/3* DKO compared to WT pro-B cells are shown for the *CD79α* and *Foxo1* loci; some of these sites coincide with E2A and/or PU.1 binding sites identified by ChIP-seq ([@bib27]; [@bib51]), and CpG sites with low methylation (5mC + 5 hmC) at these regions in WT cells show increased methylation in *Tet2/3* DKO cells ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Together these data point to a significant association between chromatin accessibility, TET protein activity (i.e. presence of 5hmC) and the binding of two transcription factors, PU.1 and E2A, with key roles in B cell development.

Notably, consistent with a previous study ([@bib4]), a fraction of the commonly accessible regions (especially those with the lowest ATAC-seq signals) corresponded to regions with significant CTCF binding in pro-B cells ([@bib51]), suggesting these regions are potent insulators ([@bib69]). In contrast, CTCF binding sites were not enriched in the WT\>DKO and DKO\>WT DARs ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). These results suggest that regulation of insulator accessibility is likely TET-independent and imply that multiple mechanisms exist to regulate accessibility in different chromatin contexts.

Increased DNA methylation at enhancers correlates with decreased accessibility {#s2-5}
------------------------------------------------------------------------------

In addition to mapping 5hmC by CMS-IP, we characterized the methylome of WT and *Tet2/3* DKO pro-B cells by whole-genome bisulfite sequencing (WGBS), which does not distinguish 5hmC from 5mC, or 5fC and 5caC from unmodified C ([@bib31]; [@bib61]). Based on the striking global loss of 5hmC in DKO pro-B cells as judged by the highly selective CMS-IP method ([@bib32]; [@bib62])([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}), all unconverted C's identified by WGBS were assigned to 5mC. Notably, the methylation landscapes were similar between WT and *Tet2/3* DKO pro-B cells, with 872 regions showing increased methylation and 258 showing decreased methylation in DKO pro-B cells ([Figure 5](#fig5){ref-type="fig"}). Analysis of these differentially methylated regions (DMRs) showed that DMRs with increased methylation in DKO cells compared to WT (DKO\>WT DMRs) were concurrently less accessible ([Figure 5A](#fig5){ref-type="fig"}, left; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}, compare first and second columns), and had originally been modified with 5hmC in WT pro-B cells ([Figure 5A](#fig5){ref-type="fig"}, *right*; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}, see third column), suggesting that TET activity is required for antagonizing DNA methylation and maintaining accessibility at these regions. Consistent with the role of TET in regulating enhancer accessibility (shown above), the majority of regions with increased methylation in DKO cells compared to WT (72.5%) show characteristics of enhancers: location distal to transcription start sites ([Figure 5B](#fig5){ref-type="fig"}) and relative enrichment for H3K4me1 over H3K4me3 ([Figure 5C](#fig5){ref-type="fig"}) and were enriched for E2A and PU.1 binding ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}; compared to randomly sampled regions in [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Together these results emphasize the strong correlation between chromatin accessibility, TET enzymatic activity based on generation of 5hmC, and maintenance of DNA demethylation at the enhancer regions marked by 5hmC. It has yet to be established, however, whether loss of 5hmC or increased 5mC plays a more significant role in the decreased chromatin accessibility in *Tet2/3* DKO pro-B cells.10.7554/eLife.18290.012Figure 5.TET proteins demethylate and modulate the accessibility of enhancers.DNA isolated from WT and *Tet2/3* DKO pro-B cells (two replicates each) were bisulfite-treated and sequenced to analyze the genome-wide DNA cytosine methylation. Differential methylation regions were analyzed as described in Materials and Methods, and 872 and 258 regions were found to have more methylation in DKO ('DKO \> WT DMRs\' in red) and WT (DKO\<WT DMRs' in blue), respectively. (**A**) Regions with increased methylation in *Tet2/3* DKO are highly enriched in 5hmC and more accessible in WT compared to *Tet2/3* DKO. *Left*, the log~2~ ratio between ATAC^WT^ and ATAC^DKO^ was calculated for the indicated regions (bin size = 10 bp) and the means were plotted. *Right,* 'DKO \> WT methylation' regions were marked with 5hmC in WT pro-B cells. The mean RPKM values for 5hmC enrichment (detected by CMS-IP) were plotted for each set of regions. (**B--C**) Differentially methylated regions bear the features of enhancers. (**B**) Distance of differential methylated sites to the closest transcription start sites (TSSs) was plotted as histogram as in [Figure 4C](#fig4){ref-type="fig"}. (**C**) Relative enrichment of H3K4me1 and H3K4me3 at the differential methylated regions was plotted as in [Figure 4D](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.012](10.7554/eLife.18290.012)10.7554/eLife.18290.013Figure 5---figure supplement 1.TET proteins demethylate and modulate the accessibility.(**A--B**) Differentially methylated regions (DMRs) were analyzed as described in Materials and Methods, and 827 and 258 regions were found to have more methylation in DKO (upper panel in (**A**); 'DKO \> WT DMRs' in red) and WT (lower panel in (**A**); 'WT \> DKO DMRs' in blue), respectively. The first two columns show the ATAC-seq signal from WT (ATAC^WT^) and *Tet2/3* DKO (ATAC^DKO^) for indicated regions (center of DMR ± 1500 bp), followed by the 5hmC signal from WT pro-B cells on the third column. ChIP-seq for E2A and PU.1 are shown on the right. Randomly sampled regions were used to show the background signals in (**B**).**DOI:** [http://dx.doi.org/10.7554/eLife.18290.013](10.7554/eLife.18290.013)

Functional and physical interaction between TET proteins and E2A/PU.1 {#s2-6}
---------------------------------------------------------------------

Our results so far pointed to a strong functional interaction between TET proteins and two key transcription factors expressed in pro-B cells, E2A and PU.1: briefly, we observed TET activity (deposition of 5hmC and subsequent demethylation) at enhancers marked by the binding of E2A and PU.1, but not EBF, Foxo1 or Oct2 ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). We confirmed the functional interaction by transducing BCR-Abl1-transformed pre-B cells with lentiviruses encoding two independent shRNAs against E2A and PU.1 respectively, then examining the DNA modification status of the 3' and distal Eκ enhancers by bisulfite sequencing ([Figure 6](#fig6){ref-type="fig"}). The shRNAs reduced the amount of E2A and PU.1 proteins substantially ([Figure 6---figure supplement 1A and B](#fig6s1){ref-type="fig"}), and increased the average level of DNA methylation at the first and second CpGs of the distal Eκ enhancer by 2- to 3-fold ([Figure 6A and B](#fig6){ref-type="fig"}), a magnitude similar to that observed in *Tet2/3* DKO pro-B cells ([Figure 3D](#fig3){ref-type="fig"}).10.7554/eLife.18290.014Figure 6.Lineage-specific transcription factors cooperate with TET protein in inducing Igκ enhancer demethylation.(**A**) Depletion of E2A increases DNA modification (5mC + 5 hmC) at the distal Eκ enhancer. WT BCR-Abl-transformed pre-B cells were transduced with two independent shRNAs against E2A or scrambled shRNA as a control. Methylation of 3'Eκ and dEκ was determined by bisulfite sequencing in the control or E2A-depleted cells. E2A knockdown is verified by immunoblotting ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Data are the summary of two independent experiments. Error bars show the range of duplicates. (**B**) Depletion of PU.1 increases DNA modification (5mC + 5 hmC) at the distal Eκ enhancer. As in (**A**), methylation of 3'Eκ and dEκ enhancers was analyzed by bisulfite sequencing after PU.1 knockdown. PU.1 knockdown is verified by immunoblotting ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Error bars show the range of duplicates. (**C**) Tet2 directly interacts with PU.1 and E2A. E2A and PU.1 were immunoprecipitated from WT or *Tet2/3* DKO BCR-Abl pre-B cell nuclear extract in the presence of ethidium bromide and benzonase to prevent indirect \'interaction\' via DNA. Co-immunoprecipitated proteins were probed with anti-Tet2. Input loaded was 2.5%. Note that a different secondary antibody was used for PU.1 and E2A to avoid the interference of IgH and IgL and thus weaker signal. (**D--E**) E2A and PU.1 facilitate the binding of Tet2 to dEk. E2A (**D**) and PU.1 (**E**) were depleted by shRNAs as in (**A**) and (**B**) and the association of Tet2 to Igκ enhancers or control regions (*Gadph* and *Igκ* introns) were assessed by ChIP-qPCR. Data are representative for at least two experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.014](10.7554/eLife.18290.014)10.7554/eLife.18290.015Figure 6---figure supplement 1.Efficient knockdown of E2A and PU.1.WT Abl-transformed pre-B cells were transduced with two individual shRNAs targeting E2A (**A**) and PU.1 (**B**) and the respective protein level was detected by immunoblotting. Actin (**A**) and GAPDH (**B**) were used as loading controls.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.015](10.7554/eLife.18290.015)10.7554/eLife.18290.016Figure 6---figure supplement 2.Tet2/3-deficiency has limited effect on genome-wide PU.1 binding.PU.1 binding patterns in cultured WT and *Tet2/3* DKO pro-B cells were analyzed by ChIP-seq, with two biological replicates for each genotype. (**A**) Similar global PU.1 binding in WT and *Tet2/3* DKO cells. Reads were to reference genome (mm9) by Bowtie2 and the peaks were called with MACS2 (-q 0.05). All peaks identified from all samples were merged to generate a master peak set, which were used as regions of interest for subsequent analysis by MEDIPS. Mean signals (in RPKM) for each peak was plotted, with those from *Tet2/3* DKO on X-axis and WT on Y-axis. (**B**) Venn diagram showing the overlapping between WT and *Tet2/3* DKO PU.1 peaks. Differential binding peaks between WT and *Tet2/3* DKO were selected with MEDIPS based on adjusted p≤0.1. Note that \> 99.9% of the peaks are not significantly different between WT and *Tet2/3* DKO pro-B cells. Details of unique regions are shown in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}. (**C**) Genome browser view of PU.1 ChIP-seq tracks from two replicates each for WT (black) and *Tet2/3* DKO (red) at Igκ enhancers as in [Figure 4E](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.016](10.7554/eLife.18290.016)

Based on these data, we tested the possibility of a physical interaction between TET proteins and E2A and/or PU.1. We found that indeed, TET2 co-immunoprecipitated with E2A and PU.1 ([Figure 6C](#fig6){ref-type="fig"}); the interaction was direct, since we used benzonase (a nuclease that degrades both DNA and RNA) and the DNA intercalator ethidium bromide to prevent false positive interactions indirectly mediated by contaminating nucleic acids in cell extracts. These findings suggested that E2A and PU.1 recruit TET proteins to enhancers, where they increase chromatin accessibility by depositing 5hmC and facilitating DNA demethylation.

We tested the recruitment hypothesis by using ChIP-qPCR to evaluate the presence of TET2 at the 3' and distal Eκ enhancers, in pro-B cells depleted of E2A or PU.1 ([Figure 6A and B](#fig6){ref-type="fig"}). Indeed, recruitment of TET proteins to the distal Eκ enhancer was significantly diminished in cells depleted for either E2A or PU.1 ([Figure 6D and E](#fig6){ref-type="fig"}). Notably, recruitment of TET2 to the 3'Eκ enhancer was not significantly affected ([Figure 6D and E](#fig6){ref-type="fig"}); this is entirely consistent with the fact that we observed increased methylation under the same conditions at the distal Eκ enhancer but no increase, or a much smaller increase, at the 3'Eκ enhancer ([Figure 6A and B](#fig6){ref-type="fig"}). The difference could be due to a requirement for additional factors (other than E2A or PU.1 alone) at the 3'Eκ enhancer, or to a threshold effect stemming from the stronger binding of E2A and PU.1 to the 3'Eκ compared to the dEκ enhancer ([Figure 4E](#fig4){ref-type="fig"}).

PU.1 has been proposed to be a \'pioneer\' transcription factor capable of association with \'closed\' chromatin ([@bib21]; [@bib27]). Consistent with this notion, we found that the genome-wide binding of PU.1 was virtually indistinguishable between WT and *Tet2/3* DKO pro-B cells ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), suggesting that PU.1 is upstream of TET and enlists TET activity to modulate the accessibility of bound enhancers. Nonetheless, these data suggest a tight functional relationship between TET proteins and the key transcription factors during B cell development.

Tet2 enzymatic activity is necessary to promote Igκ expression and chromatin accessibility {#s2-7}
------------------------------------------------------------------------------------------

The availability of the in vitro system allowed us to ask whether TET catalytic activity was required for Ig**κ** expression ([Figure 7](#fig7){ref-type="fig"}). For unknown reasons, we could not efficiently express full-length Tet2 or Tet3 in pro-B cells, but we did achieve short-lived expression of isolated Tet2 catalytic domain (Tet2CD) when we used a retroviral vector containing a blasticidin resistance gene ([Figure 7A](#fig7){ref-type="fig"}; the cells expressed Tet2CD for \~1 week after drug selection was initiated, after which expression declined rapidly). Under these conditions, *Tet2/3* DKO BCR-Abl pre-B cells reconstituted with catalytically-active Tet2CD showed increased Ig**κ** germline and IgC**κ** transcription ([Figure 7B](#fig7){ref-type="fig"}); they also displayed decreased DNA methylation at the 3' and distal Eκ enhancers, compared to mock-transduced cells ([Figure 7C](#fig7){ref-type="fig"}). Cells transduced with a catalytically-inactive version of Tet2CD (HxD mutant ([@bib42]; [@bib72]) were functionally inert ([Figure 7B and C](#fig7){ref-type="fig"}), despite the fact that the mutant protein was recruited to the 3' Eκ and distal Eκ enhancers as or almost as effectively as the catalytically active version ([Figure 7D](#fig7){ref-type="fig"}). Expression of Tet2CD, but not its HxD mutant, also restored chromatin accessibility at the 3'Eκ and distal Eκ enhancers ([Figure 7E](#fig7){ref-type="fig"}) as well as at a genome-wide level ([Figure 7F](#fig7){ref-type="fig"}) in *Tet2/3* DKO pro-B cells. Importantly, re-expression of Tet2CD was able to restore the VκJ rearrangement in *Tet2/3* DKO pre-B cells ([Figure 7G](#fig7){ref-type="fig"}), demonstrating the functional relevance of enhancer accessibility to biological outcome.10.7554/eLife.18290.017Figure 7.Tet2CD rescues Igκ expression, promotes demethylation and accessibility of 3'Eκ and distal Eκ enhancers.(**A--B**) The enzymatic activity of Tet2 is required to promote Irf4 expression and Ig**κ** germline transcription. BCR-Abl-transformed *Tet2/3 DKO* pre-B cells were transduced with retrovirus expressing Tet2CD, the corresponding Tet2CD HxD catalytic inactive mutant or empty vector (mock) together with a blasticidin resistance gene. Seven days post blasticidin selection, expression of *Tet2* (**A**), C**κ**, Ig**κ** germline transcripts and *Irf4* was determined by real time PCR (**B**). Error bars represent the standard deviation of three independent experiments. \*, p\<0.01 in Student's *t* test. (**C**) The enzymatic activity of Tet2 is required to promote 'demethylation' (loss of 5mC + 5 hmC) at Ig**κ** enhancers. BCR-Abl-transformed *Tet2/3 DKO* pre-B cells were transduced as in (**B**), and the DNA modification status of the 3' and distal Eκ enhancers was analyzed by bisulfite sequencing. Error bars indicate the range of values obtained in two independent experiments. (**D**) Tet2 associates with the Igk enhancers. WT, *Tet2/3* DKO, and DKO transduced with Tet2CD or Tet2CD HxD Abl-transformed pre-B cells were used as input and Tet2 binding to indicated regions was detected by ChIP-qPCR. The signal was normalized to corresponding samples immunoprecipitated with Ig. (**E**) Tet2CD restores chromatin accessibility at the Ig**κ** enhancers in *Tet2/3 DKO* cells. *Tet2/3 DKO* pro-B cells were transduced with retrovirus containing Tet2CD-IRES-Thy1.1 (Tet2CD), Tet2CD HxD mutant-IRES-Thy1.1 (Tet2CD HxD) or empty vector (mock). Thy1.1^+^ cells were sorted and chromatin accessibility was analyzed through ATAC-seq. (**F**) Tet2 requires its enzymatic activity in promoting chromatin accessibility. TET-regulated accessible regions (WT\>DKO DARs) were identified as in [Figure 4A](#fig4){ref-type="fig"}, and chromatin accessibility of these regions were plotted in WT pro-B cells, or *Tet2/3 DKO* pro-B cells reconstituted with Tet2CD, Tet2CD HxD or empty vector (mock). Histogram shown is distribution of ATAC-seq reads (normalized to 10 million reads depth) over 750 bp downstream or upstream of the peak center. Verification of Tet2 expression by immunoloblotting is shown in [Figure 8A](#fig8){ref-type="fig"}. (**G**) Tet2CD restores VκJ recombination in Tet2/3 DKO pre-B cells. Abl-transformed pre-B cells transduced with Tet2CD or Tet2CD HxD were treated with Gleevec to induce VκJ rearrangement and analyzed as in [Figure 2C](#fig2){ref-type="fig"} by ligation-mediated-PCR.**DOI:** [http://dx.doi.org/10.7554/eLife.18290.017](10.7554/eLife.18290.017)

TET proteins regulate the expression of IRF4 {#s2-8}
--------------------------------------------

In addition to decreased levels of Ig**κ** germline transcripts, *Tet2/3* DKO cells showed a significant decrease in *Irf4* mRNA and protein levels ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). Expression of IRF4 protein and mRNA required TET catalytic activity, since re-expression of Tet2CD restored mRNA and protein levels of IRF4 whereas the Tet2CDHxD mutant did not ([Figures 7B](#fig7){ref-type="fig"} and [8A](#fig8){ref-type="fig"}). Thus in addition to VκJ rearrangement, TET proteins regulate the expression of IRF4, which binds to 3'Eκ and potentially dEκ and regulates Ig light chain rearrangement and control pre-B cell development ([@bib53]). Nonetheless, over-expression of IRF4 marginally induced Igκ gene transcription and did not affect 3'Eκ and dEκ methylation in the absence of TET ([Figure 8B and C](#fig8){ref-type="fig"}). These results suggested that IRF4 is induced via TET catalytic activity and then functions downstream of TET proteins in regulating early B cell development.10.7554/eLife.18290.018Figure 8.TET regulates expression of IRF4.(**A**) Immunoblotting for Tet2 and IRF4 in Tet2/3 DKO BCR-Abl cells transduced with Tet2CD or Tet2CD HxD mutant. (**B**) Reconstitution with Irf4 only marginally rescued Ig**κ** expression in the *Tet2/3 DKO* cells. Tet2/3 DKO cells were transduced with retrovirus expressing IRF4 and IgCκ and IgκGL transcription was analyzed by qRT-PCR. (**C**) Re-expression of IRF4 has no effect on enhancer methylation in the absence of Tet2/3. Enhancer methylation status of cells form (**B**) was analyzed by bisulfite sequencing. (**D**) Working model of TET-mediated regulation of the Igκ locus. During early B cell development, the pioneer transcription factor PU.1 binds at various locations including the Igκ enhancers (e.g. 3'Eκ and dEκ shown here; *left*). Subsequently, presumably after IgH rearrangement, PU.1 and potentially E2A recruit TET proteins, facilitating the deposition of 5hmC and DNA demethylation. These TET-dependent activities increase enhancer accessibility, likely resulting in increased binding of additional transcription factors (*middle*). In the absence of TET proteins, the enhancers remain methylated and are less accessible for transcription factors (*right*). In addition, TET proteins regulate the expression of IRF4, a transcription factor important for the induction of Igκ rearrangement (*top*).**DOI:** [http://dx.doi.org/10.7554/eLife.18290.018](10.7554/eLife.18290.018)

Discussion {#s3}
==========

We have shown that mice with a germline deletion of *Tet2* in conjunction with *Mb1Cre*-driven deletion of *Tet3* display a block in B cell development at the pro-B to pre-B transition, reflective of decreased Ig**κ** rearrangement and expression. A profound loss of TET function is necessary, since mice lacking only Tet2 or Tet3 in B cells have no obvious B cell phenotypes. By acute Cre-mediated deletion of *Tet3* in cultured pro-B cells and rescue with Tet2, we have demonstrated that TET proteins concurrently regulate Ig**κ** germline transcription and the DNA methylation status of the 3' and distal Eκ enhancers, through a mechanism that requires TET catalytic activity.

There are well-established correlations among histone/ DNA modifications, chromatin accessibility and B cell development ([@bib4]; [@bib73]). DNA cytosine demethylation, most likely mediated by TET enzymes, has a role in organizing genome domains by affecting the binding of CTCF ([@bib4]; [@bib20]). Moreover, conditional *Dnmt3a/b* deletion results in early V**κ**-J**κ** rearrangement, increased expression of Ig**κ** germline transcripts, and decreased DNA methylation at Ig**κ** enhancers ([@bib55]). BRG1, the catalytic (ATPase) component of the SWI/SNF chromatin remodeling complex, and the chromatin reader BRWD1, have both been implicated in early B cell development ([@bib9]; [@bib54]). Indeed, Yancopoulos and Alt postulated more than 30 years ago that Ig locus accessibility is critical for Ig germline transcription and V(D)J rearrangement ([@bib80]). Our data suggest that Tet2 and Tet3 maintain chromatin accessibility at Ig**κ** locus enhancers as well as at many other promoters and enhancers in pro-B cells. While many protein complexes can modulate chromatin accessibility, the fact that acute deletion of TET function almost eliminates Ig**κ** germline transcription, in a manner that can be rescued by a TET catalytic domain, implies that the TET enzymatic activity has a primary and essential role.

The expected consequence of decreased accessibility is decreased binding of transcription factors to the poorly accessible sites. We have shown that genomic regions that are less accessible in *Tet2/3* DKO compared to WT pro-B cells are enriched for E2A and PU.1 binding motifs, and conversely, a subset of validated E2A and PU.1 binding sites, including the Ig**κ** enhancers, are less accessible in *Tet2/3* DKO pro-B cells. Notably, both transcription factors are involved in maintaining the demethylated status of the distal Eκ enhancer. PU.1, a key transcription factor in both the myeloid and lymphoid lineages, functions in macrophages as a \'pioneer\' transcription factor capable of enhancing chromatin accessibility by binding linker regions between nucleosomes, thereby facilitating the modification of neighboring histones and the binding of other transcription factors ([@bib21]; [@bib27]). Consistent with a previous finding in macrophages that both TET2 and DNMT3b co-immunoprecipitate with PU.1 ([@bib18]), we report here that TET2 co-immunoprecipitates with both PU.1 and E2A in developing B cells. Loss of TET2 and TET3 has a limited effect on the binding of PU.1 ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), suggesting that PU.1, and potentially E2A, recruit TET proteins to Igκ and other enhancers where they render the enhancers permissive for additional and/or more stable binding of those and other transcription factors ([Figure 8D](#fig8){ref-type="fig"}).

IRF4 and IRF8 are functionally redundant for the rearrangement of Ig light chains during pro-B to pre-B transition ([@bib52]), while EBF1 is imperative for the pre-pro-B to pro-B transition ([@bib49]). Our data show that in addition to regulating Ig**κ** germline transcription, TET2 and TET3 proteins are required for the expression of IRF4 and, to a lesser extent, IRF8. Ectopic IRF4 expression induced Ig**κ** germline transcription as well as premature Ig**κ** rearrangement in WT pro-B cells ([@bib6]), but ectopic expression of IRF4 in *Tet2/3* DKO cells only marginally increased Ig**κ** germline transcription. Moreover, expression of IRF4 in *Tet2/3* DKO cells had no effect on the DNA modification status of the Ig**κ** enhancers, suggesting that IRF4 and IRF8 function at a late stage, after transcription factors such as PU.1 and E2A have cooperated with TET enzymes to facilitate enhancer accessibility. Interestingly, CpG dinucleotides are present in at least one potential IRF4 binding site in both the 3'Eκ and dEκ enhancers ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), hinting that TET-mediated demethylation may be required for efficient binding of IRF4 at these enhancers. Finally, although we did not examine EBF1 because of lack of enrichment of its binding sites in TET-regulated accessible regions of the genome, EBF1 has been shown to increase both chromatin accessibility and DNA demethylation in B progenitor cells ([@bib7]), and to interact with TET2 in a cancer cell line ([@bib23]).

Our reconstitution experiments show clearly that TET-mediated changes in DNA modification status and chromatin accessibility can be rescued by re-expression of the TET2 catalytic domain in *Tet2/3* DKO pro-B cells. Although for technical reasons, we were unable to reconstitute the cells with full-length Tet2, it is not surprising that we observed a substantial restoration with the catalytic domain alone: many documented interactions of TET proteins with their partners involve the catalytic domain (e.g. TET1-OGT ([@bib3]), TET2-IDAX ([@bib39])), and Tet2 lacks a covalently associated CXXC domain that would be expected to target it to genomic regions containing unmethylated CpGs ([@bib39]).

Our current study focuses on the function of Tet2 and Tet3 in early B cell development, but our data indicate that TET proteins also have a role in mature B cells. Specifically, we observed an age-related decline of mature B cells in *Tet2/3* DKO mice, suggesting that Tet2 and Tet3 are important for B cell homeostasis. Despite this, we observed a fully penetrant development of B cell lymphomas in all *Tet2/3* DKO mice, consistent with our recent finding that acute deletion of Tet2 and Tet3 in hematopoietic stem/ precursor cells results in acute myeloid leukemia ([@bib2]). A recent study characterizing DNA methylation dynamics during human B cell differentiation revealed distinct demethylation patterns between early B cells and mature B cells ([@bib45]); demethylation in early human B cell development mainly occurs at enhancers, consistent with our observations in mice.

Bestor ([@bib5]) and Schübeler ([@bib65]) have persuasively argued that DNA methylation and demethylation are not \'instructive\' for gene transcription but rather are byproducts of altered transcription. In contrast, our data suggest that at least at Ig**κ** enhancers in pro-B cells, the increase in DNA methylation that results from TET loss-of-function can be a determining (\'instructive\') factor for the observed decrease in Ig**κ** germline transcription. However, our data also show that acute depletion of E2A results in increased DNA methylation at the distal Eκ enhancer, thus connecting transcription factor binding to DNA demethylation as postulated ([@bib5]; [@bib65]). The simplest scenario is a positive feedback loop in which E2A, PU.1 and other transcription factors ([@bib18]; [@bib23]; [@bib77]) recruit TET proteins to enhancers, thus facilitating TET-mediated DNA modification; the recruited TET proteins, via DNA demethylation, maintain chromatin accessibility at these regions, promoting increased binding of E2A and other transcription factors such as PU.1 ([Figure 8D](#fig8){ref-type="fig"}). Future studies will reveal how lineage-specific transcription factors, chromatin regulatory proteins and TET enzymes together orchestrate cell fate determination and gene expression in B cells and other cell types.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

*Tet2^fl/fl^*, *Tet2^-/-^* and *Tet3^fl/fl^* mice were generated as described ([@bib41][@bib42], [@bib40]). *Mb1Cre* mice were obtained from Dr. Changchun Xiao and originally from Dr. Michael Reth ([@bib28]). All mice were in the C57BL/6 background.

RNA extraction, cDNA synthesis and quantitative Real-Time PCR {#s4-2}
-------------------------------------------------------------

Total RNA was isolated with RNeasy plus kit (Qiagen, Germnay) and cDNA was synthesized using SuperScript III reverse transcriptase (Thermo Fisher, Waltham, MA). Quantitative PCR was performed using FastStart Universal SYBR Green Master mix (Roche, Germany) on a StepOnePlus real-time PCR system (Thermo Fisher). Gene expression was normalized to *Actb*. Primers were listed in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

Derivation of *Tet2/3* DKO pro-B cells in vitro {#s4-3}
-----------------------------------------------

Total bone marrow cells from *Tet2^-/-^Tet3^fl/fl^* mice were cultured in ɑ-MEM medium with 20% FBS and IL-7 (Peprotech, Rocky Hill, NJ; 10 ng/ml) on OP9 feeder cells for seven days, and transduced with retrovirus containing Cre-IRES-GFP. GFP^+^ cells were sorted 5--7 days after transduction and maintained as above. Cells were routinely monitored for mycoplasma contamination and were negative.

To obtain BCR-Abl transformed pre-B cells, pro-B cells were transduced with retrovirus encoding a BCR-ABL fusion protein (p210, Addgene). Three days after transduction, cells were removed from IL-7 and OP9. To induce Igκ locus rearrangement, cells were treated with Gleevec (10 μM) for indicated times, and double strand breaks at the Jκ1 RSS1 region were quantified by ligation-mediated PCR as described ([@bib17]).

To knockdown E2A and PU.1 in WT BCR-ABL transformed pre-B cells, cells were transduced overnight with lentivirus generated from pLKO.1 based shRNAs, including shScramble, shE2A-1, shE2A-2, shPU.1--1, and shPU.1--2 similar to previously described ([@bib56]). Cells were selected with puromycin at 18 hr post-transduction and continuously for 72 hr. shRNA target sequences are as follow: shE2A-1, CTGCACCTCAAGTCGGATAAG; shE2A-2, TTTGACCCTAGCCGGACATAC; shPU.1--1, AACAGAGCTGAACAGTTTGGG; shPU.1--2,TTCTGATACGTCATGCGCTTG.

Immunoprecipitation {#s4-4}
-------------------

Nuclear extracts from WT and *Tet2/3* DKO Abl-preB cells were immunoprecipitated with anti-PU.1 and anti-E2A in the presence of benzonase (Sigma, St. Louis, MO; final 500 U/mL) and ethithum bromide (Sigma; 100 μg/mL) to prevent indirect pulldown via DNA binding. Resulting proteins and 2.5% of input nuclear lysate were blotted with anti-TET2, -PU.1, and -E2A antibodies. HRP-conjugated polyclonal goat-anti-rabbit antibodies were used for detecting TET2. For PU.1 and E2A detection, blots were stripped, and probed with primary and then secondary monoclonal antibody specific for rabbit IgG conformation (Cell Signaling Technology, Danvers, MA) to minimize reactivity with IgH and IgL at around 50 and 20 kDa, respectively. Note that the overall signal was lower for E2A and PU.1 due to the secondary antibody used.

Flow cytometry and antibodies {#s4-5}
-----------------------------

For cell surface staining, cells were stained with indicated antibodies in FACS buffer (1% FBS and 0.1% NaN~3~ in PBS) for 30 mins on ice, washed, and fixed in 1% paraformaldehyde in PBS. Cytofix/Cytoperm kit (BD Bioscience, Franklin Lakes, NJ) was used for intracellular staining. Samples were analyzed with LSR Fortessa (BD Biosciences) and FlowJo (FlowJo LLC, Ashland, OR). The following antibodies were used in this study and were purchased from BD, eBioscience (San Diego, CA), or Biolegend (San Diego, CA): CD19 (clone 6D5), B220 (clone RA-3-6B2), CD25 (PC61), IgM (R6-60), IgD (11--26c.2a), CD43 (S7), CD179α (R3), cKit (2B8), Igκ (187.1), Igμ (Il/41). The following antibodies were used for immunoblotting and ChIP: anti-E2A (Santa Cruz, Dallas, TX; V18), anti-PU.1 (Santa Cruz, T-21), anti-IRF4 (Santa Cruz, M-17) and anti-TET2 (Abcam, United Kingdom;ab124297).

Igκ rearrangement analysis {#s4-6}
--------------------------

To analyze *Ig***κ** rearrangements, a degenerate V**κ** primer (GGC TGC AGS TTC AGT GGC AGT GGR TCW GGR AC) and an Ig**κ** intron primer (AAC ACT GGA TAA AGC AGT TTA TGC CCT TTC) were used; Quantitation of V**κ**-J**κ**1 rearrangement was done by qPCR with these primers: degV**κ**: GGC TGC AGS TTC AGT GGC AGT GGR TCW GGR AC and **κ**-J1-R: AGC ATG GTC TGA GCA CCG AGT AAA GG.

Enrichment-based 5hmC-mapping (CMS-IP) {#s4-7}
--------------------------------------

CMS-IP was performed similar to pervious described ([@bib32]; [@bib63]). Briefly, genomic DNA from in vitro cultured pro-B cells was isolated with PureLink Genomic DNA kit (Thermo Fisher) and were spiked-in with *c*l857 *Sam7* λDNA (Promega,Madison, WI) and PCR-generated, hmC-containing puromycin-resistant gene at a ratio of 200:1 and 100,000:1, respectively. DNA was sheared with a Covaris E220 (Covaris), end-repaired, A-tailed, ligated with methylated Illumina adaptors (NEB, Ipswich, MA), and bisulfite-converted (MethylCode Bisulfite Conversion Kit, Thermo Fisher). Bisulfite-converted DNA was denatured and immunoprecipitated with anti-CMS serum. Immunoprecipitated DNA was PCR-amplified with barcoded primers (NEBNext Multiplex Oligos for Illumina, NEB) for 15 cycles with Kapa HiFi Uracil+ (Kapa Biosystems, Wilmington, MA). Resulting libraries were sequenced with a HiSeq2500 system for 50 bp paired-end reads (Illuminia, San Diego, CA). The sequence reads were mapped to mm9 with Bismap, and CMS-enriched genomic regions were identified using the 'findPeaks\' command in HOMER with the \'histone' mode and default parameters ([@bib27]).

Amplicon bisulfite sequencing {#s4-8}
-----------------------------

Genomic DNA was bisulfite-treated according to the manufacturer's instruction (MethylCode Bisulfite Conversion Kit, Thermo Fisher), and target sequences were amplified by PCR. The PCR products were TA-cloned and sequenced as individual clones. Alternatively, PCR products were ligated with Illumina sequencing adaptors, re-amplified and sequenced using a Miseq platform (Illuminia). For Sanger sequencing of individual clones, at least 15 sequences were obtained from each sample and aligned to the target sequences using BLAST. For bisulfite sequencing using Miseq, reads were aligned to the targets with BS-Seeker2 ([@bib24]), and the sequencing depth was adjusted to at least 20 times for each. Average bisulfite conversion efficiencies were above 99%, calculated based on C to T conversion frequencies at non-CpG sites.

Whole genome bisulfite sequencing {#s4-9}
---------------------------------

Genomic DNA from in vitro cultured WT and DKO pro-B cells was prepared similar to above for CMS-IP without spiking-in hmC-containing DNA. The adapter-ligated fragments were amplified for four cycles, cleaned up, and sequenced for an approximately 30x coverage per base. We employed BSMAP v2.74 ([@bib79]) to align paired-end reads from bisulfite-treated samples to the mm9 mouse reference genome allowing four mismatches. Reads mapping to multiple locations in the reference genome with the same mapping score (multiple mappers) were removed as well as the 5' ends bearing a quality lower than 20 (-v 4 w 2 r 0 -q 20). Bisulfite conversion efficiency was estimated based on cytosine methylation in non-CpG context. For all the samples the bisulfite conversion efficiency was higher than 0.9936. Duplicated reads caused by PCR amplification were removed by BSeQC v1.2.0 ([@bib50]) applying a Poisson P-value cutoff of 1e-5. Consequently, a maximum of three stacked reads at the same genomic location were allowed and kept for further analysis. In addition, BSeQC was employed for removing DNA methylation artifacts introduced by end repair during adaptor ligation. Finally, overlapping segments of two mates of a pair were reduced to only one copy to avoid counting the same region twice during DNA methylation quantification.

Methylation calling {#s4-10}
-------------------

To estimate CpG DNA methylation at both DNA strands, we executed the methratio.py script, from BSMAP v2.74 ([@bib79]) (-t 0 g 1 -x CG -i correct).

DMR discovery {#s4-11}
-------------

We used Regression Analysis of Differential Methylation (RADMeth; methpipe V.3.4.2) ([@bib70]) for computing individual differentially methylated sites with the regression command, and posterior grouping into differentially methylated regions (DMRs) with the adjust and merge commands, (p.value 0.01).

ChIP-seq {#s4-12}
--------

In vitro cultured pro-B cells were fixed with 1% formaldehyde at room temperature for 10 min at 1×10^6^ cells/mL in media and then quench with 125 mM glycine. Nuclei were isolated and sonicated with Covaris E220 for 1200 s. Resulting chromatin was pre-cleared, immunoprecipitated with the indicated antibodies overnight, washed, and digested with proteinase K (Thermo Fisher) and RNaseA (Qiagen) at 65°C to de-crosslink overnight. DNA was purified (Zymo ChIP DNA Clean and Concentration Kit; Zymo Research, Irvine, CA) and libraries were prepared with NEBNext Ultra kit (NEB) and sequenced on Illumina Hiseq 2500 for single-end 50 bp reads.

ATAC-seq {#s4-13}
--------

ATAC-seq libraries were prepared as described ([@bib10]). Briefly, 50,000 in vitro cultured pro-B cells were lysed in 25 μl ATAC-seq lysis buffer and tagged with transposase (Illumina, Nextera DNA Library Prep Kit). ATAC-seq libraries were sequenced on an Illumina Hiseq platform for paired-end 2×50 bp reads. The sequences were first mapped to the mouse genome (mm9) with bowtie (parameters: -m 1 -X 2000). The mapped reads were filtered to discard mitochondrial reads, and PCR duplicates were removed with Samtools rmdup. The accessible regions were then determined with MACS2 (-q 0.05), and the all peaks identified from two replicates from both WT and DKO were merged to generate a master peak set, which were used as regions of interest for subsequent analysis by MEDIPS ([@bib48]). Differentially accessible regions were identified with FDR adjusted *p* value of 0.1. Commonly accessible regions used for analysis have adjusted *p* value higher than 0.1 and less than 4-fold difference between mean RPKM of two ATAC-seq replicates from WT and DKO. All mouse ENCODE blacklisted regions were removed ([@bib19]). The numbers for WT DARs, commonly accessible, and DKO DARs are 1303, 44668, 1192, respectively. Random genomic regions were generated with Bedtools shuffle with commonly accessible regions as input (n = 44668). HOMER annotatePeaks was used for identifying the distance from peaks to TSS. Motifs enriched in the preferential accessible regions were identified through HOMER (findMotifsGenome.pl --size given) with commonly accessible regions as background ([@bib27]).

To analyze the histone modifications and transcription factor binding associated with accessible regions, previous published ChIP-seq data were reanalyzed by mapping to reference genome (mm9) with Bowtie2 ([@bib46]). For histone marks enrichment analysis, differential and common peaks called by MEDIPS were extended for ±250 bp and the number of reads from H3K4me1 and H3K4me3 ChIP-seq datasets were retrieved and the RPKM was calculated by MEDIPS and used for scatter plot. Heatmaps and histograms were generated using Deeptools 2 ([@bib64]) with a bin size of 10 bp (normalized using RPKM) and region of ±1500 bp from the peak center. Log~2~ ratio between WT and DKO merged ATAC-seq data was calculated by Deeptools 2 bamCompare.

Published data sets {#s4-14}
-------------------

The following published ChIP-seq data sets were used in this study: Oct2 (GSM537990), EBF (GSM546524), PU.1 (GSM537996), E2A (GSM546523), H3K4me1 (GSM546527), H3K4me3 (GSM546529), FOXO1 (GSM546525), CTCF (GSM546526), bisulfite sequencing (GSE31971).

Ethic statement {#s4-15}
---------------

All animal works were performed according to protocol (AP128-AR2-0516) approved by the Institutional Animal Care and Use Committee at La Jolla Institute.
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Major datasets {#s7}
--------------

The following dataset was generated:

Chang X,Lio CW,Zhang J,Hogan PG and Rao A,2016,Role of Tet proteins in B cell development,<http://www.ncbi.nlm.nih.gov/bioproject/PRJNA324297>,Publicly available at the NCBI BioProject database (accession no: PRJNA324297)

The following previously published datasets were used:

Heinz S,Benner C,Spann N,Bertolino E,Lin YC,Laslo P,Cheng JX,Murre C,Singh H,Glass CK,2010,Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21512>,Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE21512)

Lin YC,Jhunjhunwala S,Benner C,Heinz S,Welinder E,Mansson R,Sigvardsson M,Hagman J,Espinoza CA,Dutkowski J,Ideker T,Glass CK,2010,A global network of transcription factors, involving E2A, EBF1 and FOXO1, that orchestrates the B cell fate,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21978>,Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE21978)

Hodges E,Molaro A,Dos Santos CO,Thekkat P,Song Q,Uren P,Park J,Butler J,Rafii S,McCombie WR,Smith AD,2011,Directional DNA methylation changes and complex intermediate states accompany lineage specificity in the adult hematopoietic compartment,<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31971>,Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE31971)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Tet2 and Tet3 cooperate with B lineage-specific transcription factors to regulate chromatin accessibility\" for consideration by *eLife*. Your article has been favorably evaluated by Jessica Tyler as the Senior Editor and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. We understand that the required additional work is extensive and possibly quite expensive, but the reviewers have affirmed the importance of the suggested experiments.

Summary:

Lio et al., studied B cell development in Tet2/3 double knock-out (DKO) mice with genotype *Tet2^-/-^ Tet3^fl/fl^ Mb1cre*. They found a strong block at the pro-B to pre-B cell transition, and a corresponding decrease of mature B cells in the spleen. They also found reduced κ light chain gene rearrangements in DKO pre-B cells, correlating with increased CpG methylation within two enhancers located 3\' of C**κ**. Chromatin accessibility measured by ATAC-Seq revealed approximately 6000 sites with reduced accessibility in ex vivo expanded DKO pro-B cells, most of which fell in regions marked with H3K4me1. Tet2/3-regulated enhancers were enriched for binding sites of the transcription factors E2A and PU.1 and shRNA-mediated knockdown of E2A and PU.1 in a BCR-ABL-transformed pre-B cell line resulted in increased methylation at 2 out of 5 sites tested. Partial demethylation was induced at these residues by expressing the Tet2 catalytic domain in a cell line from DKO mice. In addition, loss of Tet2/3 not only impairs DNA demethylation of the κ enhancers but also binding of transcription factor IRF4, suggesting that IRF4 binding at κ enhancers is regulated by Tet2,3 DNA demethylation. They conclude that DNA demethylation by Tet2/3, in part through recruitment by E2A and PU.1, controls κ gene rearrangements in particular and enhancer methylation and accessibility status more generally.

All three reviewers thought the manuscript was interesting and represented a significant advance in defining roles of Tet2/3 in B cell development. All three reviewers also thought that additional mechanistic studies were needed to more fully support some of the major conclusions. The manuscript was viewed to present two parallel themes; one focused on roles of Tet2/3 on κ locus methylation, germline transmission and DNA rearrangement and the other on broader roles of Tet2/3 in controlling the chromatin landscape. With respect to the first theme, the studies of the κ locus do not in themselves explain the developmental block at the pro- to pre-B cell transition. With respect to broader roles of Tet2/3, the authors suggest roles of PU.1 and E2A in recruiting these enzymes to specific genomic locations, but do not examine this possibility directly. In addition, while the manuscript addresses global roles of demethylating enzymes, there is there is no global analysis of differentially methylated regions in the genome.

Essential revisions:

1\) Additional experiments are needed to establish that PU.1 and/or E2A function to recruit Tet2/3 to specific genomic targets. These would include; ChIP-seq analysis of PU.1 and E2A in the DKO pro-B cells to demonstrate that these factors can still access their sites in the absence of Tet2 or Tet3. ChIP or ChIP-seq analysis of Tet2 and/or Tet3 in PU.1 and/or E2A knockdown cells should be performed to demonstrate that these factors are required for Tet2/3 recruitment. If Abs directed against Tet2 or Tet3 are an issue, an epitope tagged catalytic domain of Tet2, which is exploited in the complementation analysis, can be used (see point 2). Co-immunoprecipitation experiments should be performed to evaluate whether or not PU.1 and/or E2A form protein complexes with Tet2/3 in solution.

2\) ChIP or ChIP-seq experiments are needed to establish that the epitope tagged Tet2 catalytic domain is specifically targeted to the κ enhancers. The ability of the Tet2 catalytic domain to drive κ rearrangement should be tested using the assay employed to analyze the consequences of loss of Tet2,3 on κ rearrangement.

3\) There is no global analysis of differentially methylated regions in the genome, though the paper deals with de-methylating enzymes. Instead, ATAC seq is used as a means of assessing the ability of transcription factors to establish regions of open chromatin. However, increases or decreases in ATAC seq peaks could result from effects of the Tet2/3 DKO that are not due to local changes in DNA methylation (e.g., changes in expression of transcription factors). Thus, a global analysis of DNA methylation in the Tet2/3 DKO would substantially strengthen the relationship between DNA methylation, ATAC sensitivity and PU.1/E2A and contribute to an improved understanding of the developmental block.

10.7554/eLife.18290.030

Author response

*\[...\] All three reviewers thought the manuscript was interesting and represented a significant advance in defining roles of Tet2/3 in B cell development. All three reviewers also thought that additional mechanistic studies were needed to more fully support some of the major conclusions. The manuscript was viewed to present two parallel themes; one focused on roles of Tet2/3 on κ locus methylation, germline transmission and DNA rearrangement and the other on broader roles of Tet2/3 in controlling the chromatin landscape. With respect to the first theme, the studies of the κ locus do not in themselves explain the developmental block at the pro- to pre-B cell transition. With respect to broader roles of Tet2/3, the authors suggest roles of PU.1 and E2A in recruiting these enzymes to specific genomic locations, but do not examine this possibility directly. In addition, while the manuscript addresses global roles of demethylating enzymes, there is there is no global analysis of differentially methylated regions in the genome.*

*Essential revisions:*

*1) Additional experiments are needed to establish that PU.1 and/or E2A function to recruit Tet2/3 to specific genomic targets. These would include; ChIP-seq analysis of PU.1 and E2A in the DKO pro-B cells to demonstrate that these factors can still access their sites in the absence of Tet2 or Tet3.*

We have performed ChIP-seq analysis for PU.1 in WT and *Tet2/3* DKO pro-B cells with two biological replicates each (new [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Consistent with our model that PU.1 as a pioneer transcription factor to recruit Tet proteins, the global PU.1 binding patterns are virtually indistinguishable between WT and DKO. Of \>46,600 peaks identified from both genotypes, only 18 and 4 peaks were selectively occupied (with adj. p ≤ 0.01) in WT and DKO, respectively. Upon examination, none of these 22 peaks were near the Ig**κ** locus or other loci known to be involved in Igκ recombination (new [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Thus, we conclude that the loss of TET proteins has a very minor effect, if any, on PU.1 binding. Unfortunately, we encountered technical difficulties in performing E2A ChIP and the results were inconclusive.

*ChIP or ChIP-seq analysis of Tet2 and/or Tet3 in PU.1 and/or E2A knockdown cells should be performed to demonstrate that these factors are required for Tet2/3 recruitment. If Abs directed against Tet2 or Tet3 are an issue, an epitope tagged catalytic domain of Tet2 which is exploited in the complementation analysis can be used (see point 2).*

We appreciate the excellent points brought up by the reviewers. We performed ChIP-qPCR for endogenous Tet2 and for ectopically expressed Tet2CD and Tet2CD HxD mutant. All three proteins associate with 3'Eκ and dEκ (new [Figure 7D](#fig7){ref-type="fig"}). We then analyzed the binding of endogenous Tet2 at these enhancers in PU.1- and E2A-depleted cells and found that Tet2 binding to dEκ was substantially decreased when either transcription factor was depleted with shRNAs (new [Figures 6D and E](#fig6){ref-type="fig"}), consistent with increased DNA methylation at this enhancer upon PU.1 or E2A knockdown ([Figures 6A and B](#fig6){ref-type="fig"}).

*Co-immunoprecipitation experiments should be performed to evaluate whether or not PU.1 and/or E2A form protein complexes with Tet2/3 in solution.*

We have performed co-immunoprecipitation of endogenous PU.1 or E2A with Tet2 in Abl-transformed pre-B cells and have showed that Tet2 directly associates with both PU.1 and E2A (new [Figure 6C](#fig6){ref-type="fig"}). To exclude potential indirect interactions due to the presence of contaminating nucleic acids, the experiments were performed in the presence of ethidium bromide and benzonase, a DNA intercalator and a nuclease that cleaves both DNA and RNA, respectively.

*2) ChIP or ChIP-seq experiments are needed to establish that the epitope tagged Tet2 catalytic domain is specifically targeted to the κ enhancers. The ability of the Tet2 catalytic domain to drive κ rearrangement should be tested using the assay employed to analyze the consequences of loss of Tet2,3 on κ rearrangement.*

As mentioned above, we found that ectopically expressed Tet2 catalytic domain (Tet2CD) and its catalytically inactive mutant, Tet2CD HxD, were well expressed in *Tet2/3* DKO pro-B cells (Western blotting, [Figure 8](#fig8){ref-type="fig"}) and associated with the 3'Eκ and dEκ enhancers (ChIP-qPCR, new [Figure 7D](#fig7){ref-type="fig"}). However only Tet2CD, but not Tet2CD HxD, was able to induce Igκ rearrangement and restore chromatin accessibility at the Ig**κ** locus ([Figure 7G](#fig7){ref-type="fig"}), demonstrating that Tet2 catalytic activity is required and that the decrease in chromatin accessibility and Igκ rearrangement in *Tet2/3* DKO pro-B cells is a reversible phenomenon.

*3) There is no global analysis of differentially methylated regions in the genome, though the paper deals with de-methylating enzymes. Instead, ATAC seq is used as a means of assessing the ability of transcription factors to establish regions of open chromatin. However, increases or decreases in ATAC seq peaks could result from effects of the Tet2/3 DKO that are not due to local changes in DNA methylation (e.g., changes in expression of transcription factors). Thus, a global analysis of DNA methylation in the Tet2/3 DKO would substantially strengthen the relationship between DNA methylation, ATAC sensitivity and PU.1/E2A and contribute to an improved understanding of the developmental block.*

As recommended by the reviewers, we performed whole-genome bisulfite sequencing (WGBS) for WT and *Tet2/3* DKO pro-B cells (two replicates each) and the data are shown in the new [Figure 5](#fig5){ref-type="fig"}. In general, as opposed to global changes, loss of *Tet2/3* resulted in specific localized changes of DNA methylation, with 872 and 258 regions with increased and decreased methylation, respectively (new [Figure 5](#fig5){ref-type="fig"}).

In interpreting these data, it should be noted that bisulfite sequencing does not distinguish between 5mC and 5hmC. Given that the regions that lose accessibility in *Tet2/3* DKO compared to WT are enriched in 5hmC in WT cells ([Figure 4B](#fig4){ref-type="fig"}), and that 5hmC levels are dramatically decreased in DKO cells (new [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), the increase in 5mC+5hmC observed at the 872 regions in DKO cells compared to WT underestimate the real magnitude of the increase in methylation (5mC). Nonetheless, our data show clearly that the regions with increased methylation in *Tet2/3* DKO pro-B cells are concomitantly less accessible (new [Figure 5A](#fig5){ref-type="fig"}), suggesting that the decreased chromatin accessibility in DKO cells correlates both with loss of 5hmC and with increased DNA methylation as expected. To further demonstrate the direct causal relationship between TET proteins and accessibility, expression of Tet2CD, but not Tet2CD HxD, was able to restore accessibility to Ig**κ** enhancers and globally at other regions ([Figures 7D, E](#fig7){ref-type="fig"}). These data strongly suggest TET protein activity (hydroxymethylation followed by demethylation) facilitates chromatin accessibility, although it has yet to be established whether loss of 5hmC or increased 5mC plays a more significant role in decreased chromatin accessibility in *Tet2/3* DKO pro-B cells.

Regarding the relationship between transcription factors, TET proteins, and chromatin accessibility, we performed ChIP-seq analysis for PU.1 as mentioned above. The overall binding patterns of PU.1 are virtually indistinguishable between WT and DKO (new [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Given that PU.1 directly binds TET2 (new [Figure 6C](#fig6){ref-type="fig"}), and PU.1 depletion results in lower TET2 binding to dEκ (new [Figure 6E](#fig6){ref-type="fig"}), we propose that PU.1 first binds to less-accessible nucleosomal DNA and recruits TET2/3, which then remodels the dEκ enhancer for further recruitment of additional transcription factors and/or chromatin regulators. For the convenience of the reader, this hypothesis is now depicted schematically in the new [Figure 8D](#fig8){ref-type="fig"}.
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